BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11465948)

  • 1. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia.
    Hall PD; Virella G; Willoughby T; Atchley DH; Kreitman RJ; Frankel AE
    Clin Immunol; 2001 Aug; 100(2):191-7. PubMed ID: 11465948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
    Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
    Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein.
    Hall PD; Beagle KL; Garrett-Mayer E; Frankel AE
    Anticancer Drugs; 2008 Nov; 19(10):1007-11. PubMed ID: 18827566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor eliminates acute myeloid leukemia cells with the potential to initiate leukemia in immunodeficient mice, but spares normal hemopoietic stem cells.
    Terpstra W; Rozemuller H; Breems DA; Rombouts EJ; Prins A; FitzGerald DJ; Kreitman RJ; Wielenga JJ; Ploemacher RE; Löwenberg B; Hagenbeek A; Martens AC
    Blood; 1997 Nov; 90(9):3735-42. PubMed ID: 9345060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice.
    Hall PD; Kreitman RJ; Willingham MC; Frankel AE
    Toxicol Appl Pharmacol; 1998 May; 150(1):91-7. PubMed ID: 9630457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The majority of children and adolescents with acute myeloid leukemia have detectable anti-DT388-GMCSF IgG concentrations, but at concentrations that should not preclude in vivo activity.
    Hall PD; Razzouk BI; Willoughby TE; McLean TW; Frankel AE
    J Pediatr Hematol Oncol; 2002 Oct; 24(7):521-6. PubMed ID: 12368687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials.
    Frankel AE; Ramage J; Latimer A; Feely T; Delatte S; Hall P; Tagge E; Kreitman R; Willingham M
    Protein Expr Purif; 1999 Jun; 16(1):190-201. PubMed ID: 10336877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
    Black JH; McCubrey JA; Willingham MC; Ramage J; Hogge DE; Frankel AE
    Leukemia; 2003 Jan; 17(1):155-9. PubMed ID: 12529673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies.
    Williams MD; Rostovtsev A; Narla RK; Uckun FM
    Protein Expr Purif; 1998 Jul; 13(2):210-21. PubMed ID: 9675065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute myeloid leukemia cells in G0 phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colony-stimulating factor/diphtheria toxin fusion proteins.
    Jedema I; Barge RM; Frankel AE; Willemze R; Falkenburg JH
    Exp Hematol; 2004 Feb; 32(2):188-94. PubMed ID: 15102480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
    Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
    Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys.
    Hotchkiss CE; Hall PD; Cline JM; Willingham MC; Kreitman RJ; Gardin J; Latimer A; Ramage J; Feely T; DeLatte S; Tagge EP; Frankel AE
    Toxicol Appl Pharmacol; 1999 Jul; 158(2):152-60. PubMed ID: 10406930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor.
    Bendel AE; Shao Y; Davies SM; Warman B; Yang CH; Waddick KG; Uckun FM; Perentesis JP
    Leuk Lymphoma; 1997 Apr; 25(3-4):257-70. PubMed ID: 9168436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
    Perentesis JP; Waddick KG; Bendel AE; Shao Y; Warman BE; Chandan-Langlie M; Uckun FM
    Clin Cancer Res; 1997 Mar; 3(3):347-55. PubMed ID: 9815691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF.
    Wadhwa M; Skog AL; Bird C; Ragnhammar P; Lilljefors M; Gaines-Das R; Mellstedt H; Thorpe R
    Clin Cancer Res; 1999 Jun; 5(6):1353-61. PubMed ID: 10389919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF).
    Rini B; Wadhwa M; Bird C; Small E; Gaines-Das R; Thorpe R
    Cytokine; 2005 Jan; 29(2):56-66. PubMed ID: 15598439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia.
    Hall PD; Willingham MC; Kreitman RJ; Frankel AE
    Leukemia; 1999 Apr; 13(4):629-33. PubMed ID: 10214872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells.
    Feuring-Buske M; Frankel A; Gerhard B; Hogge D
    Exp Hematol; 2000 Dec; 28(12):1390-400. PubMed ID: 11146161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein.
    Frankel AE; Hall PD; Burbage C; Vesely J; Willingham M; Bhalla K; Kreitman RJ
    Blood; 1997 Nov; 90(9):3654-61. PubMed ID: 9345050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
    Perentesis JP; Gunther R; Waurzyniak B; Yanishevski Y; Myers DE; Ek O; Messinger Y; Shao Y; Chelstrom LM; Schneider E; Evans WE; Uckun FM
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2217-27. PubMed ID: 9815618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.